Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
Abstract B-cell non-Hodgkin lymphoma (B-NHL) is a group of heterogeneous disease which remains incurable despite developments of standard chemotherapy regimens and new therapeutic agents in decades. Some individuals could have promising response to standard therapy while others are unresponsive to s...
Saved in:
Main Authors: | Zixun Yin (Author), Ya Zhang (Author), Xin Wang (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2021-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma
by: Maria Giraudo, et al.
Published: (2024) -
Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
by: Shinichi Makita, et al.
Published: (2019) -
Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment
by: Xuejia Kang, et al.
Published: (2024) -
Chimeric antigen receptor T cell therapy for multiple myeloma
by: Kana Hasegawa, et al.
Published: (2019) -
The FDA's Regulatory Framework for Chimeric Antigen Receptor‐T Cell Therapies
by: Peter Marks
Published: (2019)